| Prev Close | 14.71 |
| Open | 14.65 |
| Day Low/High | 14.55 / 14.98 |
| 52 Wk Low/High | 7.48 / 18.00 |
| Volume | 374.10K |
| Avg Volume | 409.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 49.53M |
| Market Cap | 695.94M |
| EPS | -2.80 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Conference Call Scheduled for Thursday, March 15, 2018 at 8:30 a.m. ET
Investors considering a purchase of Karyopharm Therapeutics Inc stock, but cautious about paying the going market price of $14.80/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $12.50 strike, which has a bid at the time of this writing of $1.80.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Karyopharm Therapeutics Inc , where a total of 802 contracts have traded so far, representing approximately 80,200 underlying shares. That amounts to about 69.4% of KPTI's average daily trading volume over the past month of 115,550 shares.
Investors eyeing a purchase of Karyopharm Therapeutics Inc shares, but cautious about paying the going market price of $11.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $10 strike, which has a bid at the time of this writing of $1.65.
The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 335,533 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,387,184, an increase of 16.35% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
- Fourteen Abstracts Selected, Including Three Oral Presentations -
Conference Call Scheduled for Thursday, November 2, 2017 at 8:30 a.m. ET
The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 424,282 share decrease in total short interest for Karyopharm Therapeutics Inc , to 2,081,351, a decrease of 16.93% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.
